Because nobody else will move off their lazy asses and check things I moved and checked.
ClinicalTrials.gov is a funny site. It even lets you check change history. Here is an interesting timeline for IPIX prurisol 2b trial.
Nov 9, 2016 changes
Study is now recruiting
Primary completion date is set to July 2017
Study completion date as set to June 2017
...
and so it stays until
July 16, 2017
Primary completion date is changed to December 2017
Study completion date is changed to December 2017.
Meanwhile, things were percolating in IPIX PR stream:
Dec 19, 2016 - A sunny projection with important tidbit
'Interim analysis of 6-week data with readout is anticipated in 2Q2017, with full study top-line results in 3Q2017'
May 9, 2017 - Reality starts to set in
'Recruitment trended slower than projected due to competition from other companies also testing psoriasis drugs. To expedite enrollment, the Company has added additional investigator sites, with a total of 28 sites now actively recruiting patients, and expects interim analysis, with top-line results, to be completed in 3Q2017.'
May 11, 2017 - Important milestone regarding enrollment (and viability of interim report, if you know how to think).
'An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 percent of the 189 participants that researchers hoped for.
The therapy’s developer, Cellceutix Corporation, said it expects to release the trial’s initial results during the third quarter of 2017.'
August 28, 2017 - Full enrollment
'Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has met the goal of 189 patients enrolled in its ongoing Phase 2b clinical study of Prurisol for the treatment of moderate-to-severe psoriasis. The final number of patients will be up to 199, including those awaiting final screening test results through the end of this week (September 1). Based upon the protocol for 12 weeks of Prurisol treatment and additional patient follow-up for 4 weeks, the study is expected to be completed in Q4 2017, with results to follow thereafter. Prurisol is being developed as a novel, non-biologic, orally-delivered psoriasis drug candidate.'
Feel free to ponder, embellish and distort according how you have set your mind. It may take some effort to fit the above into rigid frame - but I trust you are capable. I already know what I think.
Cheers.
